Carna Biosciences (TSE:4572) ROC %: 0.00% (As of Dec. 2025)


TSE:4572 Carna Biosciences Inc TSE:4572
25 GF Score
Price 円314.00
GF Value 円175.60
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences ROC %?

Carna Biosciences TSE:4572 -3.68% 25 ROC % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 25/100 and a GF Value™ of 円175.60 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Carna Biosciences's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 0.00%.

As of today (2026-06-26), Carna Biosciences's WACC % is 1.89%. Carna Biosciences's ROC % is -187.38% (calculated using TTM income statement data). Carna Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Carna Biosciences  (TSE:4572) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Carna Biosciences's WACC % is 1.89%. Carna Biosciences's ROC % is -187.38% (calculated using TTM income statement data). Carna Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Carna Biosciences ROC % Related Terms


Carna Biosciences ROC % Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences ROC % Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.37 -133.67 -120.05 -241.04 -394.10

Carna Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -393.35 -459.22 0.00 -306.45
TSE:4572
25GF Score
Carna Biosciences Inc TSE:4572
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences ROC % Calculation

Carna Biosciences's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-2074.972 * ( 1 - 0% )/( (481.372 + 571.638)/ 2 )
=-2074.972/526.505
=-394.10 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2772.115 - 182.259 - ( 2108.484 - max(0, 222.965 - 2737.717+2108.484))
=481.372

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1229.648 - 141.221 - ( 516.789 - max(0, 168.07 - 1175.527+516.789))
=571.638

Carna Biosciences's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (437.805 + 571.638)/ 2 )
=0/504.7215
=0.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1635.585 - 137.211 - ( 1060.569 - max(0, 184.225 - 1589.155+1060.569))
=437.805

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1229.648 - 141.221 - ( 516.789 - max(0, 168.07 - 1175.527+516.789))
=571.638

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 0.00% mean?
Carna Biosciences (TSE:4572) has a ROC % of 0.00% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' ROC % too high?
Carna Biosciences' current ROC % is 0.00%. Overall, Carna Biosciences has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' ROC % compare to VRTX and REGN?
Carna Biosciences' ROC % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current ROC % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円175.60, compared to a current price of 円314.00 — trading 78.8% above its estimated fair value. The current ROC % is 0.00%. Carna Biosciences' overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current ROC % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円314.00 is trading 78.8% above its estimated GF Value™ of 円175.60. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • ROC %: 0.00%
  • GF Value™: 円175.60 vs. price of 円314.00 (78.8% above fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
25GF Score

Get the complete analysis for TSE:4572

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円314.00
Price
円175.60
GF Value